Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.

doi:10.32604/or.2026.073799

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.

Oncology research - 1 Jan 2026

Coltelli Luigi, Orlandi Paola, Finale Chiara, Musettini Gianna, Masini Luna Chiara, Scalese Marco, Soria Giulia, Sartori Elena, Nodari Ylenia, Arrighi Giada, Bandini Arianna, Banchi Marta, Tacchi Costanza, Tang Donghao, Salvadori Barbara, Tanganelli Lucia, Giovannelli Simona, Pistelli Mirco, Cupini Samanta, Lucchesi Maurizio, Cosimi Alessandro, Lorenzini Giulia, Biasco Elisa, Caparello Chiara, Acconci Giulia, Fontana Eloise, Bona Eleonora, Farnesi Azzurra, Pellino Antonio, Marini Andrea, De Maio Ermelinda, Stasi Irene, Barbara Cecilia, Sammarco Enrico, Rosada Javier, Allegrini Giacomo, Bocci Guido

Abstract excerpt

Background: The treatment of advanced hormone receptor-positive (HR+) breast cancer has seen relevant changes in last years. However, bevacizumab remains an option when combined with paclitaxel, but no certified pharmacogenetic profiles are now usable for the prediction of its response in breast cancer patients. This study aimed to explore the pharmacogenetic interactions among single nucleotide polymorphisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Multifactor Dimensionality Reduction

Share to Paclitaxel

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Vascular Endothelial Growth Factor A

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Open in PubMed Open full text

Identifiers

PMID: 42065063
DOI: 10.32604/or.2026.073799
PMCID: PMC13126589

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.PMID 42065063Read ↗

Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.Semantic proximity Read ↗

Machine learning models to predict <i>in vivo</i> drug response via optimal dimensionality reduction of tumour molecular profilesSemantic proximity Read ↗

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.Semantic proximity Read ↗

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.Semantic proximity Read ↗

Breast cancer-associated high-order SNP-SNP interaction of CXCL12/CXCR4-related genes by an improved multifactor dimensionality reduction (MDR-ER).Semantic proximity Read ↗

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.Semantic proximity Read ↗

Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients.Semantic proximity Read ↗

Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy.Semantic proximity Read ↗

Multinomial classification to predict the most effective adjuvant combination therapies for breast cancer patientsSemantic proximity Read ↗

Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.Semantic proximity Read ↗

Methodological issues in detecting gene-gene interactions in breast cancer susceptibility: a population-based study in Ontario.Semantic proximity Read ↗

Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.